Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years later Dec 31, 2024 → Dec 31, 2028
See other at-risk trials from Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2024 to Dec 31, 2028
    • Study completion pushed from Dec 31, 2026 to Dec 31, 2030
    • Study sites: 2 to 3
    • Eligibility criteria expanded, about 219 words
  2. Start date changed from estimate of Mar 25, 2023 to Mar 28, 2023v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.
Trial Details
NCT Number NCT05768529
Lead Sponsor Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Conditions
(from sponsor)		 Relapsed or Refractory Non-Hodgkin's Lymphoma
Related terms Lymphoma, Non-Hodgkin, Recurrence
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov